Wuxi Biologics, A Leading Global Contract Research, Development, And Manufacturing Organization (Crdmo), Today Announced A License Agreement With Gsk Plc Under Which Gsk Will Have Exclusive Licenses For Up To Four Bi- & Multi-Specific Tce Antibodies Developed Using Wuxi Biologics
